spacer
Leftshadow
Point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases developed, manufactured and licensed by Chembio Diagnostic Systems, Inc.
 
 

Welcome
Chembio Diagnostic Systems, Inc. (Chembio) (OTCQB: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Founded in 1985, Chembio entered the POC testing field in the late 1990's and, in 2002, focused its business to participate in the emerging global need and opportunity for rapid HIV tests. As a result of this focus,

Chembio's revenues have grown steadily since 2003, and at a  compounded annual growth rate of 33%, from 2006 to 2010 when revenues approached $17 million.

Chembio's Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007. DPP® enables development of POC assays that provide unique features and capabilities such as multiplexing and improved control of challenging sample types, such as oral fluid. Several new tests have already been developed on DPP® including a new oral fluid HIV 1/2 test, a new five-band POC confirmatory test for HIV 1/2, and a combination screening and confirmation test for Syphilis. Prototypes of an oral fluid test for Hepatitis C and various strains of influenza have also been developed.

more...company profile (pdf download)
The Dual Path Platform (DPP®) Technology

Chembio’s Patented Point-of-Care Testing Platform

 

Dual Path Platform
(DPP®)

The Dual Path Platform (DPP®) Technology (US Patent# 7,189,522) was developed as a platform for next generation, rapid diagnostic testing. Chembio believes that this technology allows the freedom to operate in the POC sector and offers a novel, low-cost, rapid technology as an attractive alternative to established point of care formats including lateral flow.  Advantages of DPP include increased analytical and clinical sensitivity, multiplexing capabilities and quantifiable results.  The technology is available for application in diverse global diagnostic markets for human and veterinary assays, food safety, bioterrorism, environmental testing, etc. 
Rapid Tests for Earlier Treatment of HIV, Syphilis, Hepatitis and TB, using Chembio's Patented Dual Path Platform Technology
 
 

DPP Features:

  • Increased analytical and clinical sensitivity
  • Outside the standard lateral flow IP
  • Less labor intensive than EIA, PCR or WB
  • Potential ideal confirmatory test
  • Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc.
  • Multiplex capability through elimination of
    aggregation issues (ie HIV/TB, HIV 1/ 2, etc.)
  • Ideally suited for POC testing
  • Requires minimal sample volume
  • Long shelf life (up to 24 months)
  • Total test time < 20 minutes

Diverse Potential Applications include:



 
     
 
spacer
News
   

New Chembio Syphilis Product Presented at the 18th Society for Sexually Transmitted Disease Research (ISSTDR) Congress in London, England.

Click to view Poster

   
 -PRESS RELEASES -
Date: Title:
   
01/03/2012 Chembio Provides Business Update
   
11/03/2011 Chembio Reports 3rd Quarter 2011 Results
   
10/20/2011 Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
   
10/19/11 Chembio's DPP(R) International Patent Protection Expanding
   
10/11/11 Chembio Diagnostics Obtains CE Mark for Its DPP® Syphilis Screen & Confirm Assay
   
10/03/11 CHEMBIO FILES PMA MODULE II WITH FDA FOR DPP® HIV TEST
   
08/04/11 Chembio Reports 2nd Quarter 2011 Results
   
05/05/11 Chembio Reports 1st Quarter 2011 Results
   
05/03/11 FIOCRUZ Receives Regulatory Approval to Market Chembio's Syphilis Treponemal Test
   
   
  Press Releases

 
Events Calendar spacer
 
Date: Title:
   
01/12/2012 Chembio Presenting at Biotech Conference
   
   
  Events & Tradeshows
     
spacer
 
spacer
About Us read more
Leftshadow
shadow shadow shadow
   
 
     
About Events Investor Section read more About Chembio Download Company Profile